HC Wainwright Has Negative Forecast for CADL FY2025 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for Candel Therapeutics in a report issued on Wednesday, February 26th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($1.39) per share for the year, down from their previous estimate of ($1.35). HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.47) per share.

Several other research firms have also weighed in on CADL. Citigroup initiated coverage on Candel Therapeutics in a research report on Thursday, February 20th. They set a “buy” rating and a $25.00 price target on the stock. Bank of America initiated coverage on Candel Therapeutics in a research report on Friday, February 7th. They set a “buy” rating and a $15.00 price target on the stock. Finally, Canaccord Genuity Group upped their price target on Candel Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday.

Candel Therapeutics Trading Up 4.4 %

NASDAQ:CADL opened at $8.98 on Friday. The firm has a market capitalization of $291.63 million, a price-to-earnings ratio of -5.19 and a beta of -1.25. Candel Therapeutics has a 1-year low of $1.34 and a 1-year high of $14.60. The business’s fifty day moving average price is $8.35 and its 200 day moving average price is $6.76.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Baker BROS. Advisors LP acquired a new position in shares of Candel Therapeutics during the 4th quarter valued at about $25,884,000. Acorn Capital Advisors LLC bought a new stake in Candel Therapeutics during the 4th quarter valued at approximately $16,836,000. Braidwell LP bought a new stake in Candel Therapeutics during the 4th quarter valued at approximately $13,888,000. Portolan Capital Management LLC bought a new stake in Candel Therapeutics during the 4th quarter valued at approximately $6,543,000. Finally, Halter Ferguson Financial Inc. boosted its stake in Candel Therapeutics by 123.7% during the 4th quarter. Halter Ferguson Financial Inc. now owns 681,334 shares of the company’s stock valued at $5,914,000 after purchasing an additional 376,795 shares during the period. Institutional investors and hedge funds own 13.93% of the company’s stock.

Insiders Place Their Bets

In other news, CTO Seshu Tyagarajan sold 14,322 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total transaction of $103,404.84. Following the transaction, the chief technology officer now owns 96,790 shares of the company’s stock, valued at approximately $698,823.80. This represents a 12.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Paul B. Manning acquired 1,250,000 shares of the stock in a transaction dated Monday, December 16th. The shares were bought at an average cost of $6.00 per share, for a total transaction of $7,500,000.00. Following the acquisition, the director now owns 1,303,752 shares in the company, valued at $7,822,512. The trade was a 2,325.49 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 41,529 shares of company stock valued at $313,512 in the last three months. Insiders own 41.60% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.